Tyra Biosciences, Inc. (NASDAQ:TYRA) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: about US$400M · US$22.03 a share · Jefferies +7 Dealers: Jefferies (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead), Barclays (co-lead), William Blair (co-lead), Wedbush PacGrow, Raymond James, Oppenheimer & Co. Buyers: RA Capital Management (led the offering); Invus; Commodore Capital; BVF Partners; Janus Henderson Investors; Trails Edge Capital Partners; Integral Health Asset Management; TCGX; StemPoint Capital LP Use of proceeds: Advance dabogratinib development in LG-UTUC, IR NMIBC and achondroplasia, preclinical and discovery programs, working capital and general corporate purposes | Sep 14, 2026 |